News

Bladder cancer, often misunderstood, affects both men and women, not just the elderly. While smoking is a significant risk factor, genetics and chemic ...
The U.S. Food and Drug Administration on Thursday approved UroGen Pharma's drug to treat a type of bladder cancer, providing an alternative treatment as opposed to traditional surgical procedures.
Prostate and bladder cancer in men can be prevented with the right lifestyle practices. Around Father's Day 2025 is a good time to learn such tips.
Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.
Despite a recent rebuff from an FDA advisory committee, the first treatment for a specific and underserved cohort of U.S. bladder cancer patients has crossed the FDA finish line as UroGen Pharma ...
Lymphatic metastasis is associated with markedly worse prognosis in patients with bladder cancer, although surgical resection and chemotherapy can still provide long-term survival for selected ...
We conducted a retrospective cohort study of patients with bladder cancer registered in the Registro Hospitalar de Câncer da Fundação Oncocentro de São Paulo, a large state-wide database. Eligibility ...
By Josh Beckerman UroGen Pharma shares surged after the company received Food and Drug Administration approval for bladder cancer drug Zusduri, previously known as UGN-102.
BCG therapy—the gold standard treatment for non-muscle invasive bladder cancer (NMIBC), where the cancer has not penetrated the muscle layer—is one of the earliest forms of cancer ...
Offering fans an update on his cancer fight, country singer Paul Cauthen shared why he thought cancer saved his life.
In a multi-institutional study published in the European Urology journal, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at ...
About Non-Muscle Invasive Bladder Cancer (NMIBC) LG-IR-NMIBC affects around 82,000 people in the U.S. every year and of those, an estimated 59,000 are recurrent.